🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Zevra Therapeutics, Inc.

ZVRA Healthcare
$8.76 $-0.31 (-3.42%)
Market Cap: $521.26 M
Gurus Holding
3
Popularity Rank
#2782
% of Shares Held
1.82%
Net Activity (Q3 2026)
-$5.88 M

Guru Ownership Trend

Guru Analysis for Zevra Therapeutics, Inc. (ZVRA)

Zevra Therapeutics, Inc. (ZVRA), a key player in the Healthcare sector, continues to attract institutional attention.

As of Q3 2026, a total of 3 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $9.46 M.

Top institutional holders include Chuck Royce and Cliff Asness.

Institutional sentiment is currently Slightly Bearish. This is evidenced by a $5.88 M net outflow during the quarter.

Recent activity highlights Joel Greenblatt who opened a new position. Conversely, Cliff Asness reduced exposure by 28.7%.

Key Holders

Top 5 by Value

$9.97 M
$1.49 M
$381,657

Top 5 by Conviction

Recent Activity Breakdown (Q3 2026)

+$672,131.63
Total Buy Value
New Buys 1
Additions 1
-$6.55 M
Total Sell Value
Reductions 1
Sold Out 1

Guru Consensus (Q3 2026)

Based on recent activity
Net Sellers
2
Net Buyers
2

FAQs for Zevra Therapeutics, Inc. (ZVRA)

Major holders include Chuck Royce ($9.97 M), Cliff Asness ($1.49 M), Joel Greenblatt ($381,657). According to the latest reported data, 3 tracked investment managers collectively hold approximately 1.08 M shares.

According to the latest 13F reporting period, sentiment appears Bearish (Net Selling). There was a net outflow of $5.88 M, with 2 managers increasing positions and 2 managers reducing holdings.

During the most recent reporting period, 1 managers trimmed their positions, while 1 fully exited ZVRA. The total reported sell value was $6.55 M.

Yes, 1 managers opened new positions in ZVRA, and 1 increased their existing holdings. The total reported buy value was $672,131.63.

Portfolio Manager % Portfolio Activity Shares Value Report Date
0.09% Add 3.0% 909,137 $9.97 M Q3 2026
0.00% Reduce -28.7% 136,099 $1.49 M Q3 2026
0.00% New Buy 34,791 $381,657 Q3 2026
Date
Insider Name
Transaction
Value
Shares
Position / Chg
SEC Form